<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04870515</url>
  </required_header>
  <id_info>
    <org_study_id>RG1121348</org_study_id>
    <secondary_id>NCI-2021-02762</secondary_id>
    <secondary_id>P50CA097186</secondary_id>
    <secondary_id>10669</secondary_id>
    <nct_id>NCT04870515</nct_id>
  </id_info>
  <brief_title>Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study</brief_title>
  <official_title>TRIPLE-A PILOT: Actively Intercepting ADT-Induced Metabolic Aberrations in Newly Diagnosed Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the effects of a diet and physical activity intervention on blood&#xD;
      measures of lipids and insulin resistance in patients with prostate cancer undergoing&#xD;
      radiation therapy (RT) and androgen deprivation therapy (ADT). ADT effectively slows the&#xD;
      growth of prostate cancer cells, thereby enhancing the therapeutic effectiveness of RT.&#xD;
      Despite the clinical gains, ADT leads to an array of side effects including insulin&#xD;
      resistance, abnormal lipid levels, weight gain, increased visceral fat mass coupled with&#xD;
      increased muscle wasting, and quality of life deterioration. A diet and physical activity&#xD;
      intervention may intercept or prevent the abrupt metabolic and physiologic changes caused by&#xD;
      androgen deprivation therapy in prostate cancer patients receiving ADT and RT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Patients are randomized to 1 of 2 groups.&#xD;
&#xD;
      GROUP I (DIET AND PHYSICAL ACTIVITY): Patients attend 10 in-person or virtual sessions with a&#xD;
      registered dietitian over 6 months to receive instructions on a modified DASH diet. Patients&#xD;
      also attend 2 one-on-one sessions with an exercise psychologist to receive instruction to&#xD;
      complete aerobic physical activity and strength/resistance training. Patients may also&#xD;
      complete up to 21 additional supervised exercise sessions.&#xD;
&#xD;
      GROUP II (CONTROL): Patients attend a single in-person or virtual session with a registered&#xD;
      dietitian to receive standard lifestyle recommendations based on the Unites States (US)&#xD;
      dietary guidelines, activity goal of 30 minutes of physical activity 5 days/week; and&#xD;
      discussion of the health benefits of weight maintenance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of the intervention on androgen deprivation therapy (ADT)-induced changes in Homeostatic Model Assessment for Insulin Resistance</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Homeostatic model assessment of insulin resistance (HOMA-IR) will be computed from glucose and insulin concentrations. Compare change in HOMA-IR levels relative to baseline between intervention and control participants. Will be evaluated using linear regression models.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of the intervention on ADT-induced changes in body weight</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Weight will be measured at baseline and 6 months. Will be evaluated using linear regression models.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of the intervention on ADT-induced changes in waist circumference</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Waist (1&quot; above umbilicus) circumferences will be measured at baseline and 6 months. Will be evaluated using linear regression models.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of the intervention on ADT-induced changes in lean mass</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Lean mass will be measured by dual-energy x-ray absorptiometry at baseline and 6 months. Will be evaluated using linear regression models.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of the intervention on ADT-induced changes in fat mass</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Fat mass will be measured by dual-energy x-ray absorptiometry at baseline and 6 months. Will be evaluated using linear regression models.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Localized Prostate Carcinoma</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Group I (diet, physical activity)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients attend 10 in-person or virtual sessions with a registered dietician over 6 months to receive diet instructions. Patients also attend 2 one-on-one sessions with an exercise psychologist to receive instruction to complete aerobic physical activity and strength/resistance training. Patients may also complete up to 21 additional supervised exercise sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (standard lifestyle recommendations)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard lifestyle recommendations and attend an individual session with a dietitian over 20-30 minutes including US dietary guidelines, activity goal of 30 minutes of physical activity 5 days/week; and discussion of the health benefits of weight loss along with general behavior change suggestions for weight loss.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Receive standard lifestyle recommendations</description>
    <arm_group_label>Group II (standard lifestyle recommendations)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietary Intervention</intervention_name>
    <description>Receive dietary instructions</description>
    <arm_group_label>Group I (diet, physical activity)</arm_group_label>
    <other_name>Dietary Modification</other_name>
    <other_name>intervention, dietary</other_name>
    <other_name>Nutrition Intervention</other_name>
    <other_name>Nutrition Interventions</other_name>
    <other_name>Nutritional Interventions</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise Intervention</intervention_name>
    <description>Complete aerobic and strength/resistance exercises</description>
    <arm_group_label>Group I (diet, physical activity)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (diet, physical activity)</arm_group_label>
    <arm_group_label>Group II (standard lifestyle recommendations)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (diet, physical activity)</arm_group_label>
    <arm_group_label>Group II (standard lifestyle recommendations)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 40-70 years&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate, (D'Amico risk category&#xD;
             intermediate or high risk, localized or locoregional)&#xD;
&#xD;
          -  Primary treatment is RT + ADT [Zoladex, Lupron, Degarelix, and other luteinizing&#xD;
             hormone-releasing hormone (luteinizing hormone releasing hormone [LHRH])-directed&#xD;
             therapies] with standard RT dose and fractionation (anti-androgen monotherapy will not&#xD;
             be allowed&#xD;
&#xD;
          -  Physically able to undertake an exercise program&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Advanced, metastatic disease&#xD;
&#xD;
          -  Planning to join a commercial/structured diet change or fitness program&#xD;
&#xD;
          -  Have significant pre-existing T2D (poor glycemic control while on medication, defined&#xD;
             as hemoglobin A1c of &gt;= 10 within the prior 12 months) or significant pre-existing&#xD;
             cardiovascular disease (CVD) (myocardial infarction or stroke within prior six months)&#xD;
&#xD;
          -  Physician confirmed cognitive impairment or alcohol/narcotic abuse&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marian L. Neuhouser</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marian L. Neuhouser</last_name>
    <phone>206-667-4797</phone>
    <email>mneuhous@fredhutch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan L. Wright</last_name>
    <phone>206-579-8922</phone>
    <email>jlwright@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Veterans Affairs Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan L. Wright</last_name>
      <phone>206-579-8922</phone>
      <email>jlwright@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan L. Wright</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian L. Neuhouser</last_name>
      <phone>206-667-4797</phone>
      <email>mneuhous@fredhutch.org</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan L. Wright</last_name>
      <phone>206-579-8922</phone>
      <email>jlwright@uw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marian L. Neuhouser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

